Sarah Fredriksson, PhD, Chairman of the Board
PhD and M.Sc. from Lund University, Sweden. CEO of AQILION AB. Fredriksson has a background as founder and CEO of Genovis AB (listed on First North, Nasdaq OMX Nordic) and most recently CEO of Edvince AB. Currently she serves as board member of LU Holding, Edvince AB, Respiratorius AB and SwedenBIO. Former board member of AcuCort AB.
Niklas Arnberg, PhD, Director of the Board
Professor, Dept. of Virology, Inst. of Clinical Microbiology, Umeå University, Sweden. Discovered that sialic acid is the receptor for certain adenoviruses and defended his doctorial thesis in this subject in 2001. Arnberg has continued his research within this field and is one of the founders of Adenovir Pharma AB
Clas Runnberg, Director of the Board
Market economist. Runnberg has held senior executive positions in several international medtech companies including Gambro and HemoCue in Sweden; Diatek Medical Technologies, Block Medical and HemoCue, Inc. in California, in the US and Vidacare B.V. in the Netherlands. Presently he is an industrial advisor to the Swedish private equity fund Valedo, advisor to the EIT Health program and a board member of Monivent AB. Former chairman of P.U.L.S. AB (today known as AQILION AB).
Göran Wadell, MD, PhD, Deputy Director of the Board
Professor, Dept. of Virology, Umeå University, Sweden. Wadell is a recognized scientist in the field of adenovirus and one of the founders of Adenovir Pharma AB.
M.Sc.(BA). CEO/Project Leader of Adenovir Pharma AB. Currently he holds the position Vice President, New Project Investments at AQILION AB. Dellgren is a former Partner at BankInvest, Denmark and has worked with international biotech venture investments and fund management since 2000. Previous Director of Business Development at Pharmacia and various international positions in sales, marketing and business management at Pharmacia and the US pharmaceutical company, Lederle. He is board member of Cernelle AB, Sweden, former board member of Cernelle AB and he was previously board member of CMC Biologics, Denmark.
PhD, M.Sc. in chemistry from Umeå University. Vice President, Chief Business Officer at AQILION AB. Lindgren has a background in the pharmaceutical industry with key positions in the area of business development processes at AstraZeneca and Umetrics AB among others. Most recently, he held the position Senior Director, Head of Global Business Development at LEO Pharma.
M.Sc. Industrial Engineering and Management. Vice President, CFO at AQILION AB. Since 1984 Ardevall has worked in the pharma and POC diagnostic industry in various positions within Finance, most recently as CFO/Director of Finance of HemoCue.